GLP-1 Therapies Newsletter
Issue #60October 26, 20267 studies

Retatrutide cut sleep apnea events by ~20 per hour in a phase 3 trial

The GLP-1 universe keeps expanding — this week it absorbed sleep medicine, brain inflammation, and a randomized trial on decision-making in depression.

The throughline: these drugs are doing things far outside the pancreas, and researchers are still mapping the territory.

A Triple Agonist Just Cleared a Major Hurdle for Sleep Apnea 💤

  • Retatrutide — an investigational drug targeting three hormone receptors simultaneously — reduced the apnea-hypopnea index (the count of breathing interruptions per hour of sleep) by an estimated 20.0 events/hour versus placebo in adults without positive airway pressure therapy, and by 23.8 events/hour in those already using it.
  • The 52-week phase 3 trials enrolled 469 adults with obesity and at least 15 breathing interruptions per hour. Alongside the sleep numbers, participants also saw reductions in sleep-related oxygen deprivation, body weight, systolic blood pressure, and inflammation markers.
  • The mechanism is blunt but logical: less fat around the tongue and throat means a wider airway. The drug doesn't splint the airway open the way a breathing machine does — it shrinks the tissue that was closing it.

Why it matters: Positive airway pressure therapy treats the symptom. Weight-driven pharmacotherapy targets the anatomy. Retatrutide's results suggest the two strategies aren't competing — they stack.

🏆 Top 0.1% journal 🔗 The New England journal of medicine Journal Article 🗓️ Oct 22

Key Findings

Semaglutide Changed How Depressed Patients Explore Their Options 🧠

  • In a randomized controlled trial, semaglutide altered explore/exploit decision-making — the mental balance between trying new options versus sticking with known ones — in patients with major depressive disorder.
  • The study used a four-armed restless bandit task to measure this behavior, linking a metabolic drug to a cognitive process that sits at the intersection of motivation and reward.
💡 A diabetes drug just moved the needle on motivated decision-making in depression.
🔗 Psychological medicine Randomized Controlled Trial 🗓️ Oct 22

Compounded GLP-1 Prescriptions Finally Have a Paper Trail 📋

  • A JAMA study using prescription drug monitoring program data mapped compounded weight-loss GLP-1 dispensing patterns across the U.S., including rates of self-payment, out-of-state dispensing, and what ingredients — including vitamin B12 coformulations — are actually in these products.
  • This is the clearest real-world look yet at a market that has operated largely outside the visibility of clinical trial infrastructure.
💡 What's actually in compounded GLP-1s? Now there's data, not just guesses.
🔗 JAMA Journal Article 🗓️ Oct 23

Tirzepatide Outperformed Semaglutide on Weight Loss — But the Gap Has Limits

  • A head-to-head comparison (SURMOUNT-5) showed tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks in adults with obesity.
  • A multi-criteria analysis across efficacy, safety, and accessibility found tirzepatide ranked highest on most models, but an oral pill candidate ranked highest when accessibility and manufacturing scalability were weighted most heavily — a meaningful distinction for global reach.
💡 Tirzepatide wins on weight loss, but accessibility may decide real-world reach.
Top 50% journal 🔗 Omics : a journal of integrative biology Journal Article 🗓️ Oct 21

Weight Regain After GLP-1 Therapy May Hit Men's Muscles Hardest 💪

  • A review flagged that incretin-induced weight loss includes lean tissue loss, and men with obesity — who commonly have low or low-normal testosterone — may face compounded risk: reduced muscle mass, increased visceral fat, and impaired insulin sensitivity.
  • The authors propose that testosterone combination therapy could help preserve muscle during and after GLP-1 treatment, though this remains a hypothesis rather than an established protocol.
💡 Losing weight on GLP-1s is one thing; keeping muscle is a separate, unsolved problem.

GLP-1 Drugs May Quiet Brain Inflammation — In the Right Conditions 🔬

  • A review of preclinical and early clinical evidence found that GLP-1 receptor agonists can shift brain immune cells (microglia) from a pro-inflammatory state toward an anti-inflammatory one, with potential relevance for Alzheimer's disease, Parkinson's disease, and multiple sclerosis models.
  • The catch: effects appear context-dependent, and separately, a seizure-focused review found that the same drugs can have paradoxical pro-seizure effects in genetic absence epilepsy models — a reminder that 'anti-inflammatory' in the brain is not a universal outcome.
💡 GLP-1s calm brain inflammation in some models — and worsen seizures in others.

Nausea Measurement in GLP-1 Trials Is Surprisingly Sloppy 🤢

  • A narrative review found that across the major liraglutide, semaglutide, and tirzepatide obesity trials, nausea was captured through spontaneously reported adverse events — a pharmacovigilance tool — rather than any validated patient-reported symptom instrument.
  • Meanwhile, those same trials invested heavily in validated quality-of-life measures for obesity outcomes. The asymmetry may help explain why real-world discontinuation rates far exceed what trial tolerability data would predict.
💡 Trials measured nausea with the wrong tool — and real-world dropouts reflect that gap.

Implications

GLP-1 drugs are now being tested against sleep apnea, depression, kidney disease, neurodegeneration, and cancer risk — often with promising signals. The unresolved tension: most of these expansions rest on secondary endpoints or observational data, and the field still lacks a clear answer on how much benefit disappears when patients stop treatment.

Studies in this issue

Primary sources used for this newsletter.

  1. Weekly Retatrutide Treatment for Obstructive Sleep Apnea
    main storyThe New England journal of medicine2026-10-22PMID 42904878
  2. Controlling Brain Immune Cells by GLP-1 Pathways: A New Approach to Brain Inflammation
    key findingThe European journal of neuroscience2026-10-22PMID 42904474
  3. How Accurately Is Nausea Measured in Obesity Trials Using GLP-1 Treatments?
    key findingDiabetes, obesity & metabolism2026-10-23PMID 42919104